Molecular signatures of BRCAness analysis identifies PARP inhibitor Niraparib as a novel targeted therapeutic strategy for soft tissue Sarcomas

Background: Patients with advanced soft tissue sarcomas (STS) have a dismal prognosis with few effective therapeutic options. A defect in the homologous recombination repair (HRR) pathway can accumulate DNA repair errors and gene mutations, which can lead to tumorigenesis. BRCAness describes tumors...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hongyi, Tu, Jian, Zhao, Zhiqiang, Chen, Lijuan, Qu, Yueting, Li, Hongbo, Yao, Hao, Wang, Xiaoshuai, Lee, Dung-Fang, Shen, Jingnan, Wen, Lili, Huang, Gang, Xie, Xianbiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449912/
https://www.ncbi.nlm.nih.gov/pubmed/32863940
http://dx.doi.org/10.7150/thno.45763

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7449912/
https://www.ncbi.nlm.nih.gov/pubmed/32863940
http://dx.doi.org/10.7150/thno.45763

Ejemplares similares